Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Abbott's flash glucose monitor to be made available on NHS

Abbott
Posted on: 14 Sep 17

Abbott's FreeStyle Libre – a flash glucose monitor that allows diabetes patients to track their blood sugar without pricking – will be reimbursed by the NHS from 1 November, subject to local health economy approval.

The device's starter pack previously cost around £170, with readers for the sensors costing as much as £60, but will now be available for reimbursement via the NHS across England and Wales, NHS Scotland and Health and Social Care in Northern Ireland for people with type 1 and 2 diabetes who are intensively-using insulin.

The system uses a sensor the size of a £2 coin, worn on the back of the upper arm, to automatically read glucose levels. Clinical studies and real-world evidence have suggested that FreeStyle Libre users scan their glucose levels an average of at least 15 times per day, and that these higher rates of self-monitoring are strongly associated with improved glucose measures.

Chris Askew, Chief Executive of Diabetes UK, said: “Today’s announcement is fantastic news: Not since the transition from urine testing to finger-prick testing has there been such potential to transform the lives of people living with Type 1 and Type 2 diabetes through technology.

“Flash glucose monitoring can free people living with diabetes from the pain and rigour of frequent finger-prick testing, and puts them in greater control of their condition. In doing so, it has the potential to help prevent a host of devastating long-term complications. Today’s decision is testament to the commitment of campaigners, clinicians and policy makers to making this technology available."

He added: “The challenge now will be that everyone who could benefit from this technology is able to access it where they live; Diabetes UK will be looking to local decision makers to ensure people living with diabetes get proper access to this potentially life-changing technology.”

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 14/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.